| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_CDYL_0002900 | Intron-Exon-Intron | chr6:4864319-4920371 | chr6:4864085-4920137 | 279 nt | 0.4014 |
| hsa_CDYL_0003000 | Intron-Exon | chr6:4867590-4892332 | chr6:4867356-4892098 | 81 nt | 0.3951 |
| hsa_CDYL_0003100 | Intron-Exon | chr6:4867590-4892337 | chr6:4867356-4892103 | 472 nt | 0.4703 |
| hsa_CDYL_0003200 | Intron-Exon-Intron | chr6:4867590-4892613 | chr6:4867356-4892379 | 748 nt | 0.5254 |
| hsa_CDYL_0003300 | Intron-Exon-Intron | chr6:4867590-4894274 | chr6:4867356-4894040 | 63 nt | 0.4762 |
| hsa_CDYL_0003400 | Intron-Exon | chr6:4876591-4892337 | chr6:4876357-4892103 | 23 nt | 0.6087 |
| hsa_CDYL_0003500 | Intron-Exon | chr6:4879239-4892337 | chr6:4879005-4892103 | 443 nt | 0.4740 |
| hsa_CDYL_0003600 | Intron-Exon-Intron | chr6:4879239-4892613 | chr6:4879005-4892379 | 58 nt | 0.3966 |
| hsa_CDYL_0003700 | Intron-Exon-Intron | chr6:4879239-4897442 | chr6:4879005-4897208 | 129 nt | 0.3256 |
| hsa_CDYL_0003800 | Intron-Exon | chr6:4881599-4892337 | chr6:4881365-4892103 | 143 nt | 0.4476 |
A study in humans demonstrated that the circCDYL is highly expressed in early stages of hepatocellular carcinoma, bladder cancers, and breast cancer [Misir et al. DOI:10.1038/s41418-022-00948-7]. In hepatocellular carcinoma, it promotes stem-like characteristics and tumor growth via the miR-328-3p/HIF1AN axis under hypoxic conditions [Huang et al. DOI:10.3390/cells11091381]. A study in mice demonstrated that the circCDYL is decreased in myocardial tissues and hypoxia myocardial cells, where it improves cardiac function after acute myocardial infarction [Sema Misir et al. DOI:10.1038/s41418-022-00948-7].